FDA Just Approved the First mRNA Flu Vaccine for Seniors. Here’s What Nursing Homes Need to Know.

Washington, D.C. — The Food and Drug Administration has approved the nation’s first mRNA-based influenza vaccine for adults 50 and older, clearing the way for a new option in nursing home immunization programs ahead of the 2026-2027 respiratory virus season.

The vaccine, called mFLUSIVA and developed by Moderna, uses the same messenger RNA technology that powered the COVID-19 vaccines. It’s the first time this platform has been authorized for seasonal flu in the United States.

Company research involving more than 40,000 participants found the shot appears to produce stronger protection than traditional flu vaccines, according to industry reports. The FDA approved the vaccine for adults ages 50 to 64, with an accelerated approval pathway for those 65 and older conditioned on additional clinical trials.

What This Means for Nursing Homes

For operators, the approval arrives at a critical moment. Flu season preparation is already underway, and quality metrics facing increased scrutiny mean immunization rates carry more weight than ever.

mRNA vaccines offer one clear advantage: they can be updated and manufactured far more quickly than conventional flu shots. That’s significant when unexpected strains emerge, as happened during the last flu season.

The approval wasn’t guaranteed. The FDA initially declined to review Moderna’s application amid the Trump administration’s broader skepticism toward mRNA technology. The agency reversed course following pressure from pharmaceutical industry groups and public health experts. An independent advisory panel voted unanimously in June to recommend approval.

Availability and Timing

Moderna says mFLUSIVA will be available “in a few weeks” — in time for the upcoming flu season. Whether nursing homes will have access depends on federal distribution decisions and whether the vaccine gets added to recommended immunization schedules.

The approval gives seniors a new option. For an industry still navigating post-pandemic vaccination politics, it’s another variable in an already complex equation.